AR-12286 ophthalmic solution 0.5%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AR-12286 ophthalmic solution 0.5%, covering 2015-04-24 to 2015-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention [Phase 2]